PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608880
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608880
The global breast cancer brachytherapy market is estimated to be valued at USD 898.1 Mn in 2024 and is expected to reach USD 1,423.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | 898.1 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 6.80% | 2031 Value Projection: | 1,423.2 Mn |
Breast cancer brachytherapy is a form of radiation therapy that involves placing radioactive seeds or catheters directly inside breast tissue. It allows the delivery of higher doses of radiation to a contained area while lowering exposure to surrounding healthy tissues. This precision therapy plays an important role in early stage, low risk breast cancer treatment as it can often avoid disfiguring surgery while achieving high cure rates. Breast brachytherapy is typically delivered as radiation boost after lumpectomy, or used alone in elderly or medically inoperable patients. As breast cancer incidence continues rising globally due to aging populations and lifestyle changes, the breast brachytherapy market is positioned for steady growth over the coming years.
The global breast cancer brachytherapy market growth is driven by the rising breast cancer burden worldwide, growing preference for breast conserving therapies, and favorable reimbursement policies in developed countries for brachytherapy procedures. However, the market potential is hampered by difficulties in delivering brachytherapy to all patient types combined with the perception of lumpectomy alone being insufficient treatment. Key market opportunities lie in expanding the use of breast brachytherapy in developing nations, exploring combining it with other treatment modalities like chemotherapy to treat higher risk cases, and ensuring adequate training of radiation oncology specialists especially in low resource settings.
This report provides in-depth analysis of the global breast cancer brachytherapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key companies covered as a part of this study include Varian Medical Systems, Inc., Elekta AB, Eckert & Ziegler BEBIG, iCAD, Inc., Hologic, Inc., Cianna Medical, IsoRay Medical, Inc., Theragenics Corporation, C.R. Bard, Inc., Boston Scientific Corporation, Merit Medical Systems, Cook Medical, SenoRx, Inc., Nucletron B.V., and Xoft, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global breast cancer brachytherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global breast cancer brachytherapy market